Anika Therapeutics, Inc. reported a revenue of $112.8 million for the fiscal year ended December 31, 2025, reflecting a decrease of 6% compared to $119.9 million in 2024. The decline was primarily attributed to lower pricing and sales volume from its Original Equipment Manufacturer (OEM) channel, particularly with Johnson & Johnson MedTech, which accounted for 50% of total revenue. The company experienced a gross profit of $63.8 million, resulting in a gross margin of 57%, down from 63% in the previous year. This reduction in gross profit was influenced by increased manufacturing costs and higher inventory reserves.
In terms of operational changes, Anika Therapeutics underwent a strategic shift in October 2024, divesting its Arthrosurface and Parcus Medical subsidiaries to focus on its core Osteoarthritis (OA) Pain Management and Regenerative Solutions portfolios. The divestitures were completed in late 2024 and early 2025, respectively, and were aimed at enhancing profitability by concentrating on high-growth areas. The company has also initiated a full market release of its Integrity Implant System, which has shown strong adoption since its launch.
The company’s research and development expenses remained stable at $25.8 million, a slight increase from $25.5 million in 2024, as it continued to invest in its product pipeline, including the Cingal and Hyalofast products. Cingal, a next-generation OA pain management product, is currently under review for U.S. regulatory approval, while Hyalofast is in the process of seeking FDA clearance. The company is also focusing on expanding its international sales, which contributed to a 15% increase in revenue from its Commercial Channel.
Anika Therapeutics reported a net loss of $10.9 million for 2025, a significant improvement from a net loss of $56.4 million in 2024. This improvement was largely due to the absence of substantial losses from discontinued operations, which had negatively impacted the previous year’s results. The company’s cash and cash equivalents stood at $57.5 million at year-end, with no outstanding borrowings under its $75 million revolving credit facility, indicating a stable liquidity position.
Looking ahead, Anika Therapeutics aims to leverage its proprietary hyaluronic acid technology to drive growth in the OA Pain Management and Regenerative Solutions markets. The company plans to continue investing in research and development to support the commercialization of its products and is exploring potential partnerships to enhance its market presence. The management remains optimistic about the future, despite the challenges posed by competitive pressures and regulatory hurdles.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. develops and manufactures hyaluronic acid (HA)-based medical products focused on osteoarthritis (OA) pain management and regenerative orthopedic solutions. Its key offerings include viscosupplements like Monovisc and Orthovisc, and regenerative products such as the Integrity Implant System and Hyalofast scaffold. Serving global markets through direct sales and distributor networks, Anika targets clinicians and surgeons with innovative, clinically supported therapies designed to improve patient outcomes in early intervention orthopedics.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.